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Abstract
Purpose It has been proposed that biological/chemical sub-
stances in the intestine might play a role in the occurrence
and deterioration of perianal fistulas. Elimination of such un-
identified factors from the lower gastrointestinal tract might
offer a new strategy for the management of anal fistulas. The
aim of this study was to evaluate the clinical effects on non-
Crohn’s disease perianal fistula healing, and the safety and
tolerability of a new medical device that applies high-purity,
high-activity granular activated carbon locally into the rectum
twice daily of patients with perianal fistulas without any con-
comitant medication.
Methods An open, single-arm, prospective study with active
treatment for 8 weeks and an optional follow-up until week 24
(ClinicalTrial.gov identifier NCT01462747) among patients
with chronic, uncomplicated perianal fistulas scheduled for
surgery was conducted.
Results Of 28 patients included, 10 patients (35.7%) showed
complete fistula healing (closed, no discharge on palpation)
after 8 weeks; seven of these patients, corresponding to 25%
of the enrolled patients, remained in remission for up to
31 weeks. At week 8, there was a statistically significant re-
duction in the discharge visual analog scale (p = 0.04), a sig-
nificant improvement in the patient-perceived quality of life
for the category of embarrassment (p = 0.002), and a trend
toward improvement in the other assessment categories.
Conclusions The treatment was well tolerated, and patient
acceptance was high. The results support the efficacy and
safety of locally administered activated carbon for the treat-
ment of patients with chronic uncomplicated perianal fistulas
not receiving any other medication for fistula problems.
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Introduction
Perianal fistulas are often bothersome to affected patients and
may be considered to be a chronic disease because the spon-
taneous cure rate is low. Available treatment options are lim-
ited; usually, surgery is performed [1] with its associated risks.
Thus, the consequences of anal surgery potentially include
profound fecal incontinence and an impaired quality of life
[2]. Hence, there is a dire need for new treatment options for
this condition.
The etiology of perianal fistulas is believed to be
cryptoglandular infection, often in individuals with a previous
history of an anorectal abscess [3], although they may addi-
tionally arise due tomore specific causes, e.g., Crohn’s disease
(CD) [4], malignancy, or following radiation therapy [5]. The
local microbial flora in these situations may facilitate an in-
flammatory cascade and initiate production of tissue-
damaging chemical/biological substances in the perianal area
(e.g., endotoxins, oxygen-reactive species, cytokines, and
arachidonate metabolites). Such factors combined with other
tissue-damaging fecal substances like bile acids and enzymes
might lead to a local functional derangement with epithelial
defects and the occurrence of perianal fistulas. Therefore,
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elimination of unidentified substances from the gastrointesti-
nal tract might offer a novel therapeutic strategy.
Activated carbon is a well-tolerated substance with wide-
spread use owing to its outstanding nonspecific adsorptive
properties and its use for detoxification, and there is no sys-
temic absorption after oral or rectal administration. Previously
orally administered activated carbon (AST-120) has been in-
vestigated on anal fistulas in CD, however, with conflicting
results [6, 7], as its passage through the intestinal tract may
possibly influence the adsorptive capacity. Thus, by using oral
administration of activated carbon, it is uncertain how much
adsorption power is actually available when it reaches the
rectal ampulla.
However, by administration of activated carbon into the
rectum, a much higher adsorption power might be available
in the perianal region. This is the first study evaluating the
effects of activated carbon applied directly at the site of action
on the healing of non-CD perianal fistulas, by means of a new
medical device (ASTER) using a rectal applicator.
Materials and methods
Study design
An open, uncontrolled, nonrandomized, single-arm prospec-
tive study (Kulist-001, ClinicalTrials.gov identifier
NCT01462747) evaluating the efficacy and safety of a
medical device administrating activated carbon for the
treatment of chronic, uncomplicated, and non-CD perianal
fistulas was performed. The clinical study was approved by
the local scientific ethics committee and competent authority.
Patient population
Patients were in the age group of 18–75 years with suspected
perianal fistula complains requiring referrals to tertiary surgi-
cal centers. All patients underwent a clinical examination as
well as a 3D ultrasound to confirm diagnosis of active trans-
sphincteric fistulas according to Parks’ classification [8], and
to exclude extra-suprasphincteric fistula activity or other dis-
eases. Diagnosis of an active/open fistula was based on case
history, clinical, and ultrasound examination. Only patients
with active simple anal fistulas without any side tracts or cav-
ities that were assessed and scheduled for surgery (i.e., placed
on a waiting list) were given the option of being included into
the study.
There were no restrictions on therapy received prior to this
study. However, any anti-inflammatory therapy (NSAIDs),
antibiotics, or concomitant immunomodulatory therapies (in-
cluding glucocorticoids, thiopurines, and tumor necrosis
factor-α inhibitors), as well as any other therapy against fistu-
la(s), were not allowed during the trial.
Study visits and medical device
Four study data points were scheduled for patients included
into the trial: day 1, baseline (site visit); week 2 follow-up
(telephone call); week 8 follow-up (site visit), and a final
optional follow-up after a minimum of 24 weeks (site visit).
Blood samples for measurement of C-reactive protein, hemo-
globin, and white blood cell counts were collected at baseline
and week 8.
The high-purity, high-activity granular activated carbon
was delivered rectally using the medical device (QPharma,
Limhamn, Sweden). The rectal treatment was administered
twice daily with a minimum of 6 h between administrations.
The device (Fig. 1a, assembled device) is for single use only
and consists of (1) a rectal applicator with a Vaseline-
lubricated tip with a protective cap, a carbon chamber contain-
ing 1.2 g of activated carbon (EUP 2010), and a connector
tube; (2) sterile water (EUP quality) 10 ml from a plastic
container (Fresenius Kabi, Uppsala, Sweden); and (3) a 10-
ml sterile syringe (BraunMedical, Bethlehem, PA, USA). The
syringe is filled with sterile water and connected to the rectal
applicator. When injected into the rectal applicator, the sterile
water acts as a propellant to push out the activated carbon.
Endpoints
The primary endpoint of the study was the clinical eval-
uation of fistula healing, healed/not healed (healed de-
fined as closed, no discharge on palpation) at week 8.
Secondary endpoints were included change (baseline to
end of study) of perianal symptoms as assessed by the
patient (global assessment of discharge and pain report-
ed on a VAS scale), as well as impact on daily func-
tions (patient-perceived quality of life), tolerability, and
safety. Change in healing assessed by subject-reported
subjective symptoms (discharge and pain on a published
VAS scale previously used in this field [9]) were pre-
sented as percent change and absolute change from
baseline. A validated patient assessment questionnaire
earlier applied was used to evaluate patient-perceived
quality of life using the following parameters: embar-
rassment, functionality, fear of surrounding, sexual ac-
tivity, risk of spontaneous leaking, traveling and toilet
localization [10].
Statistical analysis
The sample size of a minimum of 25 patients was based on
identical statistical assumptions as described in the Fukuda
trial [7], with an estimated spontaneous remission rate of
10% and a target remission rate of 35% at week 8.
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Results
A flowchart showing the disposition of patients is provided in
Fig. 1b. Themean age of patients was 46 years (22 were males
(78.6%)). All 28 patients included were diagnosed with a
trans-sphincteric fistula, and 9 of 28 patients (32.1%) had
received nonsurgical treatment for current or previous
fistula(s).
After 8 weeks of treatment, 10 of 28 patients (35.7%)
showed complete clinical fistula healing. In addition to the
10 patients with clinical healing at week 8, four patients ex-
perienced improvements but no healing according to
predefined criteria.
Eleven of the 28 patients (39.3%) continued in the optional
24-week follow-up study (Fig. 1b). Seventeen patients already
placed on the waiting list, however, accepted surgery after
week 8 (Fig. 1b). At week 24, data were available for 9 of
10 patients (one patient withdraw informed consent, cf.
Fig. 1b) with clinical healing at week 8 (although an additional
patient did not show up to the scheduled week 24 visit but
contacted the ward by phone and reported to be without fistula
symptoms). Thus, 7 of 9 patients attending the week 24 visit,
corresponding to 25% of the original number of treated pa-
tients, had maintained remission at week 24 (or 8 of 10 pa-
tients (i.e., 29% of all patients treated) if including the patient
who reported only by telephone).
A 26-point median reduction (p = 0.04) in discharge VAS
was observed after 8 weeks, and a further median reduction of
6.5 points (i.e., 32.5 points from baseline; p = 0.005) was
observed in patients attending the week 24 follow-up.
However, no effect was observed on the pain VAS score as
assessed after 8 and 24 weeks.
For the patient assessment questionnaire at week 8,
significant improvements were observed from baseline
for the category of embarrassment (p = 0.002).
Improvements were noted for functionality, traveling, fear
of surroundings, and toilet location. At week 24, there
were significant improvements in embarrassment
(p = 0.034), health conditions (p = 0.034), and risk of
spontaneous leakage (p = 0.038).
Fig. 1 a The medical device
assembled ready for use: 1a
Rectal cannula (with cap
removed) and carbon chamber. 1b
Connection tube. 1c Vaseline
lubricated tip. 1d Activated
carbon (1.2 g). 2 Sterile water,
10 mL (EUP quality). 3 Sterile
syringe (CE-marked), 10 mL. b
Flowchart of patient disposition
during the trial (active treatment
and follow-up)
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Patient acceptance of the medical device was sound, and a
mean compliance was 99%. Four patients experienced a total
of seven adverse events during the study; all events were
judged to be mild (e.g., nausea and constipation), and all were
resolved by completion of the study without any treatment
required. Further, no clinically significant abnormal laborato-
ry results were reported during the study.
Discussion
A majority of patients with clinical healing/remission at week
8 maintained remission at week 24. The recurrence rate, for
obvious reasons, needs to be a primary endpoint [11]. Here,
the recurrence rate at 24 weeks was 22% if only the patients
with clinical healing at week 8 were considered, but if all
patients were taken into account, the recurrence rate was
75%. In comparison, for fistula plug treatment, a recurrence
rate of up to 76% has been reported [12].
Patients reported statistically significant improvements
from baseline to week 8 for the category of embarrassment
and improvements for functionality, traveling, fear of sur-
roundings, and toilet location. At week 24, statistically signif-
icant improvements in embarrassment, health conditions, and
risk of spontaneous leakage were observed.
In conclusion, a huge need for novel treatment options of
chronic, perianal fistulas exists. Rectal application of high-
purity, high-activity granular activated carbon with a new
medical device might be a promising and safe alternative treat-
ment option for patients with chronic uncomplicated perianal
fistulas and may additionally preserve sphincter function.
However, based on the data presented and the limitations of
an open study, a larger randomized, controlled trial with a
minimum of 12 months of follow-up is highly warranted.
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